BioSpectrum Asia - August 2018
Get BioSpectrum Asia along with 7,500+ other magazines & newspapers
Try FREE for 7 days
Latest and past issues of 7,500+ magazines & newspapers
Digital Access. Cancel Anytime.
Share with 4 family members.1 Year$99.99
Latest and past issues of 7,500+ magazines & newspapersDigital Access. Cancel Anytime.Share with 4 family members.Get BioSpectrum Asia
1 Year $10.99
Save 7%12 issues starting from BioSpectrum Asia November 2022 Digital Access. Cancel Anytime.Buy this issue $0.99
August 2018 issue Digital Access. - Magazine Details
- In this issue
Magazine Description
In this issue
ACCELERATING IVD INNOVATIONS The increasingly ageing population, need for rapid diagnostic results, emergence and re-emergence of infectious diseases, and growing lifestyle disorders are expected to accelerate the IVD market. IVD market is constantly evolving. Mega trends such as consolidation, automation, and reimbursement policies affect every aspect of the market. The growing importance of diagnostics in patient care is expanding beyond hospitals and laboratories to homes, long term and chronic care, and other segments in healthcare. Apart from the major trends in IVD, there are other key trends like growing digitalization of healthcare to enable a more efficient patient care continuum.
Cancel Anytime [ No Commitments ]
Digital Only
Who Needs Next Gen Vax Tech?
The COVID-19 vaccines were developed in record time. As the novel’ coronavirus mutates, the vaccine makers, too, are adapting by innovating vaccine technologies. Researchers continue to work, aiming for more potent immunity, reduced transmissibility, cheaper manufacturing, easier transport, and mutation-targeted vaccines. The novel vaccine models may facilitate rapid and effective responses to new infectious diseases, allergies, autoimmune conditions, and cancers. Vaccination programmes can be more cost-effective and efficient by achieving global outreach, maintaining vaccine potency, and optimising logistics, thus increasing global preparedness for future pandemics and disease outbreaks. Let’s explore some of the latest advancements in vaccine technology which emerged in the era of COVID-19.
India Unveils Tele Mental Health Assistance And Networking Across States
Establishing a new milestone in the field of mental health on the occasion of World Mental Health Day on October 10, Tele Mental Health Assistance and Networking Across States (Tele-MANAS), an initiative of the Union Ministry of Health & Family Welfare, Government of India, has been launched in the country.
WHO issues new framework to strengthen collaborative action onTB and comorbidities
The World Health Organisation (WHO) is launching a new framework for collaborative action on tuberculosis (TB) and comorbidities to address the limited uptake of collaborative activities to reduce the burden of TB and comorbidities and to support countries in enabling access to peoplecentred care.
Sierra Leone adds HPV jabs to routine immunisation schedule
In a move to protect adolescent girls from cervical cancer, the government of Sierra Leone, in West Africa, has introduced the Human Papilloma Virus (HPV) vaccine to the routine immunisation schedule and launched the start of a campaign to reach 153,991 girls with the vaccine.
Gavi inks agreement with Moderna for COVID-19 vaccine supply to LICs
Gavi, the Vaccine Alliance, has signed an agreement with Moderna related to the supply of COVID-19 vaccines to lower-income countries (LICs) supported by the Gavi COVAX Advance Market Commitment (AMC).
NousQ receives $175K grand prize for paediatric ear tube insertion device
MedTech Innovator, the largest accelerator of medical devices in the world, in partnership with Asia Pacific Medical Technology Association (APACMed), the first and only regional association to provide a unified voice for the medical technology industry, has announced NousQ as the winner of the 2022 Asia Pacific Accelerator programme.
Pfizer acquires Australian startup ResApp Health for 179 M
US-based Pfizer has acquired University of Queensland (UQ) startup ResApp Health Limited for $179 million. ResApp, an ASX-listed company based in Brisbane, has developed simple and inexpensive smartphone technology that can accurately identify respiratory diseases based on cough analysis.
Deep Bio explores AI support for prostate cancer diagnosis
South Korea-based startup Deep Bio Inc. has announced that it will sign trial purchase agreements with five Korean hospitals for its artificial intelligence (AI)-based prostate cancer diagnosis support software, DeepDx-Prostate Pro, through the Public Procurement Marketplace programme run by the Korean Public Procurement Service (PPS).
Rx Propellant plans Rs 3k Cr investment to build life sciences lab spaces in India
Rx Propellant, an Actis portfolio company and India’s leading life sciences infrastructure and cluster developers, has announced the launch of 9 lakh sq ft of lab spaces in Genome Valley, Hyderabad, India.
Simcere, Almirall ink S492 M deal for treating autoimmune diseases
Simcere Pharmaceutical Group, an innovation and R&D-driven pharmaceutical company, and Almirall S.A, a global biopharmaceutical company focused on skin health; have entered into an exclusive licensing agreement for Simcere’s IL-2 mutant fusion protein (IL-2 mu-Fc) autoimmune drug candidate, SIM0278.
